Home

Vision

Biotech start-up that develops novel, adjustable cancer immunotherapies

Our vision is to defeat cancer. Our aim is to fully arm the patient’s immune system to successfully fight and thus win the battle against cancer. After passive checkpoint inhibition, we are now in the wake of a new era for cancer therapeutics, and OncoQR ML is first inline.

We are developing cancer immunotherapies that harness all four natural killing mechanisms of our immune system in a tumor specific manner, which is required to defeat the cancer´s immune evading mechanisms.

About OncoQR

About OncoQR

OncoQR ML is a pre-clinical biotech-startup that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable…

Learn more

S-TIR Technology

Technology

The S-TIR™technology is an adjustable cancer immunotherapy (ACI) platform that was originally developed by S-TARget therapeutics GmbH for the…

Learn more

Collaborate with Us

Pipeline

OncoQR ML has achieved in vivo proof-of-concept (PoC) for its two prototype and lead product candidates directed against two major oncology…

Learn more

Meet the Team

The people behind

OncoQR QR ML was founded by two experienced, senior pharma professionals with top-level research & development as well as management backgrounds: Christof Langer, MSc, MBA and Geert C. Mudde, PhD.
Christof Langer
Christof Langer
CEO
Christof Langer received an international engineering degree in food- and biotechnology (MSc) from the Vienna University of Applied Sciences in...
Geert C. Mudde
Geert C. Mudde
CSO
Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the...
Kathrin Szimak
Kathrin Szimak
Business Development
After having worked for about 10 years in different Marketing and Business Development Management positions in the pharmaceutical industry...

Technology

The S-TIR™technology is an adjustable cancer immunotherapy (ACI) platform that was originally developed by S-TARget therapeutics GmbH for the treatment of severe allergic diseases and out-licensed for oncology to OncoQR ML

Therapeutic Principle

Active Checkpoint Control Immunotherapy (ACCI) activates all four naturally available tumor killing mechanisms selectively…

Learn more

Mode of Action

OncoQR ML´s cancer vaccines are based on the unique, proprietary, two-module S-TIR™ platform…

Learn more

Cancer Immunotherapy

Cancer cells have the ability to escape our immune system´s defenses – by outsmarting checkpoint molecules on our immune cells…

Learn more

News & Conferences

UPCOMING EVENTS & CONFERENCES

November 2017:

October 2017:

PRESS RELEASES

February 2016:

OncoQR announces spectacular news results with its Pancreatic Cancer Vaccine